Were Analysts Bearish Kamada Ltd. (NASDAQ:KMDA) This Week?

April 17, 2018 - By Adrian Erickson

Kamada Ltd. (NASDAQ:KMDA) Ratings Coverage

Among 2 analysts covering Kamada (NASDAQ:KMDA), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Kamada had 2 analyst reports since February 2, 2018 according to SRatingsIntel. The company was maintained on Thursday, February 8 by H.C. Wainwright. Below is a list of Kamada Ltd. (NASDAQ:KMDA) latest ratings and price target changes.

08/02/2018 Broker: H.C. Wainwright Rating: Buy New Target: $11.0 Maintain
02/02/2018 Broker: Chardan Capital Markets Rating: Buy New Target: $7 Initiates Coverage On

The stock increased 1.09% or $0.05 during the last trading session, reaching $4.65. About 12,350 shares traded. Kamada Ltd. (NASDAQ:KMDA) has declined 31.39% since April 17, 2017 and is downtrending. It has underperformed by 42.94% the S&P500.

Kamada Ltd. develops, produces, and markets specialty plasma-derived protein therapeutics. The company has market cap of $187.90 million. It operates through two divisions, Proprietary Products and Distribution. It has a 25.83 P/E ratio. The companyÂ’s respiratory products include Glassia for use in augmentation and maintenance therapy in adults with emphysema due to congenital AAT deficiency ; Bramitob to manage chronic pulmonary infection; and FOSTER for the treatment of asthma.

Kamada Ltd. (NASDAQ:KMDA) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.